Fine tuning subsets of CD4+ T cells by low-dosage of IL-2 and a new therapeutic strategy for autoimmune diseases

Article ID	Journal	Published Year	Pages	File Type
8531385	International Immunopharmacology	2018	8 Pages	PDF

Abstract

Although Interleukin-2 (IL-2) was identified almost 40â¯years ago, only recently low dosage IL-2 therapy is proved to be an effective approach to treat autoimmune diseases. The underlining mechanism is that IL-2 can fine-tune subsets of CD4+ T cells by promoting the development and maintenance of regulatory T cells (Treg) at low-dosage (ld) and enhance the functions of effector T cells (Teff) at high-dosage (hd). Since the successful clinical trials of IL-2 to treat patients with autoimmune diseases and inflammatory conditions, including Systemic lupus erythematosus (SLE) and Type 1 Diabetes (T1D), ld IL-2 therapy is a promising strategy to treat autoimmune diseases.

Keywords

alopecia areata IL-2 ITIM Treg Th17 HSCT TFH STAT5 IPEX immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome ICOS T1D ITSM SHP-2 nonobese diabetic mice VLs S region GvHD CTLA-4 IL-2 receptors TCGF T cell growth factor RAS PI3K PD-1 FOXP3 Janus kinase cDNA Complementary DNA MAPK TCRs Rheumatoid arthritis cytotoxic T lymphocyte antigen-4 Akt Amino acids Interleukin-2 Autoimmune diseases Chronic graft-versus-host disease Immune thrombocytopenia Teff forkhead box P3 Memory T cells Type 1 diabetes rat sarcoma natural killer T cells Follicular helper T cells Effector T cells NKT cells Natural killer cells Regulatory T cells Vascular leak syndrome signal transducer and activator of transcription 5 Phosphatidylinositol 3-kinase Systemic lupus erythematosus SLE Programmed death 1 NOD mice Immunoreceptor tyrosine-based inhibitory motif HCV Hepatitis C virus ITP protein kinase B mitogen-activated protein kinase Hematopoietic stem cell transplantation JAK T cell receptors